Insights into Concomitant Atrial Fibrillation and Chronic Kidney Disease

Yanan Wang¹, Yi Yang¹,* , Fan He¹,*

¹Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China
*Correspondence: fhe@tjh.tjmu.edu.cn (Fan He); yiyang@tjh.tjmu.edu.cn (Yi Yang)

Abstract

Chronic kidney disease (CKD) shows a high prevalence and is characterized by progressive and irreversible loss of renal function. It is also associated with a high risk of cardiovascular disease. The CKD population often suffers from atrial fibrillation (AF), which is associated with cardiovascular and all-cause mortality. There is a pernicious bidirectional relationship between CKD and AF: renal dysfunction can help promote AF initiation and maintenance, while unmanageable AF often accelerates kidney function deterioration. Therefore, it is necessary to determine the interactive mechanisms between CKD and AF for optimal management of patients. However, due to renal function impairment and changes in the pharmacokinetics of anticoagulants, it is still elusive to formulate a normative therapeutic schedule for the AF population concomitant with CKD especially those with end-stage kidney failure. This review describes the possible molecular mechanisms linking CKD to AF and existing therapeutic options.

Keywords: chronic kidney disease; atrial fibrillation; fibroblast growth factor; uremic toxin; anticoagulant; sodium-glucose cotransporter inhibitor; sacubitril/valsartan

1. Introduction

The prevalence of chronic kidney disease (CKD) and atrial fibrillation (AF) is rising annually. CKD is an insidious disease defined by a progressive drop in kidney function with or without renal structural changes and is a vital contributor to cardiovascular disease. Data from the health system shows that CKD affects 10% population worldwide (Fig. 1), and its global prevalence has augmented 29.3% since 1990 [1].

The most common cardiac dysrhythmia, AF, causes many adverse cardiovascular outcomes. Stroke, chronic heart failure, myocardial infarction, systemic embolic events, dementia, and venous thromboembolism are common complications of atrial fibrillation, and its prevalence ranges from 2% to 4% in adults [2]. Moreover, AF was associated with an increased risk of adverse cardiovascular events and cardiovascular mortality [3,4].

CKD and AF often share multiple common risk factors, such as age, male sex, cardiovascular disease, hypertension, diabetes, heart failure, and obesity (Fig. 2) [5–7]. A prospective cohort study including 235,818 general subjects indicated that estimated glomerular filtration rate (eGFR) decline increased the risk of AF, meanwhile, the occurrence of AF promoted the deterioration of renal function [8]. In CKD patients, 15–20% were estimated to suffer from AF, and 7.0% of the dialysis population had AF [9–11]. Conversely, CKD acts as an independent risk factor of AF. Urine albumin-to-creatinine ratio (UACR) represents a common kidney function indicator. A recent study focusing on the incidence of AF in CKD patients showed that the risk of AF increased approximately twice in UACR >300 mg/g compared with UACR <30 mg/g [Hazard Ratio (HR) 2.69; p < 0.0001] [12]. On the other hand, AF might play a significant role in CKD progression. In the Chronic Renal Insufficiency Cohort Study (CRIC) which included 3,091 participants, patients complicated with AF were at a considerably higher probability of progression to end-stage renal disease (ESRD) (HR 3.2; p < 0.0001) [13]. Similarly, a systematic review of 25 literature showed that the presence of AF among the dialysis population was associated with a higher risk of stroke (5.2 vs. 1.9 per 100 person-years) and mortality (26.9 vs. 13.4 per 100 person-years) [14]. Thus, management of AF in CKD patients is extremely imperative for physicians. This review aimed to elaborate our argument on the knowledge about patients with AF and CKD.

2. Clinical Outcomes of AF in CKD Patients

Ineffective and disordered atrial contraction and diastole lead to an impaired or loss of atrial contribution to ventricular filling. Thus, patients with AF may have symptoms like palpitation, breathlessness, fatigue, and dizziness due to irregular and inappropriately rapid ventricular rhythm and loss of “atrial kick”, while some are asymptomatic. On the other hand, sympathetic nervous system hyperactivity in CKD patients promotes conduction of atrial impulses to the ventricles with rapid ventricular rate then influence cardiac output [15]. In addition to hemodynamic disturbance resulting from AF, AF is also associated with poor clinical consequence such as stroke and death in dialysis patients [16–18]. Moreover, a cohort study named CRIC indicated
that incident AF was linked independently with an elevated incidence of heart failure, stroke, and death [19]. In another study on stages 3–4 CKD population, incident AF elevated the risk of renal function deterioration [20]. Except for the poor prognosis of AF in the CKD population, changes in the CKD coagulation systems lead to an increased risk of thrombosis and bleeding. CKD’s bleeding tendency is influenced by many aspects relevant to the secondary platelet function disorder and the heparin application in dialysis [21,22]. In conclusion, the pro-hemorrhagic state poses a challenge for the management of thromboembolism events prophylaxis in CKD patients.

3. AF in CKD

Generally, the AF pathophysiology includes three essential parts (Fig. 3): AF initiation, maintenance and progression to persistent state [23]. Atrial risk factors cause atrium changes like fibrosis, inflammation, cellular and molecular dysfunction, subsequently electrophysiological and structural remodeling raised by persistent AF leads to its perpetuation [3].

Pulmonary vein sleeves (PVs) play a major role in introducing AF [24]; its unique location, tissue construction, and ion channels conduce to ectopic electrical activity and re-entry [25]. The PV sleeves lack adjacent tissue and continuous fibers, leading to spontaneous activity and AF onset. The early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs) generation underlies ectopic activity. In the setting of prolonged action potential duration (APD), usually caused by reducing K⁺ currents or enhanced depolarizing currents (including Na⁺ and L-type Ca²⁺ currents), L-type Ca²⁺ channels recover from inactivation and facilitate the occurrence of inward current [26]. Compared with EADs, DADs have a more active role in triggering ectopic activity. Ca²⁺-handling abnormalities resulting from cardiac ryanodine receptor channel type 2 (RyR2) dysfunction, and spontaneous sarcoplasmic reticu-
lum (SR) Ca\(^{2+}\) release events (SCaEs) promote DAD both in animal models and patients with AF [27–29]. However, as the original link of DAD, Ca\(^{2+}\)/calmodulin-dependent kinase II (CaMK II) hyperphosphorylation is a crucial target in arrhythmia initiation and perpetuation. The autonomic system provides a substrate for AF development, and triggers the AF-pathophysiology by promoting Ca\(^{2+}\)-handling abnormalities. Sympathetic activation leads to CaMK II phosphorylation through β-adrenoceptor and cyclic adenosine monophosphate (cAMP) production [30]. In addition, sympathetic stimulation results in increased SR Ca\(^{2+}\) load, with concurrent positive inotropic action of cardiomyocytes.

Ca\(^{2+}\) overload plays a vital role in the persistence of CaMK II phosphorylation [30]. Oxidative stress is a feature of many diseases and is involved in Ca\(^{2+}\)-handling abnormalities. A study comparing patients with AF and sinus rhythm concluded that oxidative stress promotes AF through oxidating CaMK II. However, in CKD patients, overactive inflammatory response and the renin-angiotensin-aldosterone system (RAAS) promote reactive oxygen species (ROS) accumulation and atrial fibrosis; thus, contributing to AF progression [31,32].

Fibroblast growth factor-23 (FGF-23) is a hormone involved in the regulation of calcium-phosphorus metabolism balance and bone mineralization [33]. Elevated level of FGF-23 is associated with a higher risk of heart failure, all-cause mortality, cardiovascular mortality, and left-ventricular hypertrophy [34–36]. Both myocyte culture and animal experiments confirmed that FGF-23 can induce hypertrophic growth of cardiac cells [37,38]. Furthermore, in the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS), increased FGF-23 concentration was associated with an increased risk of AF [39]. In addition, FGF-23 binds to the FGF-receptor 4 (FGFR4) in cardiac myocytes in the defect of klotho, and induces hypertrophy through activating phospholipase C (PLC) \(\gamma\)/calcineurin/Nuclear factor of activated T-cells (NFAT) pathway [37,40]. FGF-23 also stimulated PLC \(\gamma\)/calcineurin/NFAT cascade in hepatic cells during klotho deficiency, causing elevated inflammatory cytokine secretion (tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), interleukin-2 (IL-2), and IL-6) [41]. FGF-23 and FGFR 4 expression increased in the atrial tissues of AF patients compared with the sinus rhythm population, consistent with the expression of \(\alpha\)-smooth muscle actin (α-SMA) and collagen-1. Dong and his colleagues illuminated that FGF-23/FGFR4 accentuated atrial fibrosis by inducing ROS accumulation and then regulating signal transducer and activator of transcription 3 (STAT3) and small mother against decapentaplegic 3 (SMAD3) pathways [42]. Therefore, FGF-23/FGFR4 provides a vulnerable substrate for AF (Fig. 4). In patients with uremic syndrome, indoxyl sulfate (IS) and p-cresyl sulfate (pCS) are classic toxins with high protein affinity and cardiotoxicity. It has been shown that IS promotes AF by producing atrium fibrosis and inflammatory response, and treatment with uremic toxin absorbent AST-120 alleviated these undesirable effects and then attenuated AF [43,44]. Lekawanvijit et al. [45] also demonstrated that IS might play a role in pro-fibrotic and pro-inflammation via the P38 mitogen-activated protein kinase (MAPK), P22/44 MAPK, nuclear factor kappa-B (NF-\(\kappa\)B) signaling pathway in vitro. In 5/6 nephrectomy rat models by Aoki et al. [43], oxidative stress is increased in the left atrium. In another animal experiment on rabbits, IS induced more DAD, burst firing events, and larger Ca\(^{2+}\) leakage in pulmonary vein cells, which trigger AF occurrence [44]. Furthermore, IS played a part in impairing the Mas receptor’s ability to counter the pernicious effect of angiotensin II (Ang II) via the organic anion transporter 3 (OAT3)/arylhydrocarbon receptor (AHR)/STAT3 pathway, which reduced the number of Mas receptor [46]. Thus, we conclude that IS plays a vital role in AF via the effects of inflammation, fibrosis, and oxidative stress on atrial remodeling (Fig. 4). Uremic toxin pCS may have effects similar to IS.

4. Management of AF in Patients with CKD

4.1 Rate and Rhythm Control

When the adverse effects of AF appear due to rapid ventricular rate or loss of available atrial contraction, medication strategy, including rate and rhythm control should be considered. \(\beta\)-blockers and non-dihydropyridines calcium channel blockers are recommended as first-line pharmaceutical strategies to realize rate control, and selective \(\beta_1\) re-
Here, we summarize the relevant molecular pathways and their effects. AF, atrial fibrillation; CKD, chronic kidney disease; FGF-23, fibroblast growth factor-23; IS, indoxyl sulfate; pCS, p-cresyl sulfate; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen species; TNF, tumor necrosis factor.

Receptors blocking agents are more desirable [47]. Metoprolol and carvedilol are usually prescribed by physicians to ESRD patients, metoprolol is selective β1 receptor blockers, while carvedilol is nonselective and it has greater α1 antagonism [48,49]. In a large retrospective cohort study, subgroup analysis of dialysis patients with AF showed that carvedilol was associated with higher all-cause and cardiovascular mortality. Besides, carvedilol caused more hypotension during dialysis sessions [50]. Beta-blockers are also effective in the primary prevention of atrial fibrillation in ESRD patients [51]. Nevertheless, several large-scale randomized clinical trials (RCTs) are required to provide scientific and solid evidence to explicit beta-blockers administration in patients with concomitant AF and ESRD. When rate control treatment is ineffective or has serious side effects, it is time to consider initiating rhythm control, especially in those requiring dialysis [52]. A commonly administrated rhythm control drug is amiodarone, there is no need to adjust the prescription dose even in the dialysis population [52]. Of specific interest, a novel rate control agent ivabradine is not recommended in patients with CKD at present. A meta-analysis showed an elevated risk of AF with ivabradine treatment [53]. However, another meta-analysis found that ivabradine can reduce the ventricular rate in patients with AF [54]. An uncompleted RCT Ivalbradine Block of Funny Current for Heart Control in Permanent Atrial Fibrillation (BRAKE-AF, NCT03718273) is going to demonstrate ivabradine’s inferiority in heart rate control (Table 1) [55]. We still need to keep an eye on ivabradine treatment to control heart rate in persistent AF patients.

Apart from medical treatment, catheter ablation (CA) is now a safer and effective option for patients with symptomatic and refractory AF. An observational study showed that CA improves the eGFR of CKD patients with AF [56]. However, the presence of CKD increased the recurrence of AF after CA, and we should perform an assessment of the risks and benefits before atrial fibrillation ablation.

4.2 Stroke Prevention in AF and CKD Patients

One of the irreversible outcomes caused by AF is thromboembolism, which usually results from a detachment of thrombus in the atrium cordis. For long-term management of the risk between thromboembolism and bleeding, the widely recognized CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex) guideline system identifies the population warranted prophylactic anticoagulation in patients with paroxysmal, persistent, or permanent atrial fibrillation. Oral anticoagulants are recommended strongly for AF patients with CHA2DS2-VASc score of 2 or greater in males or 3 or greater in females [57]. Anticoagulant options include the traditional drug warfarin and non-vitamin K oral anticoagulants (NOACs) (dabigatran, rivaroxaban, apixaban, and edoxaban). Compared with NOACs, warfarin administration has high-quality scientific evidence in clinical practice. However, in RCTs, the NOACs are not inferior to warfarin in preventing stroke and superior to warfarin in decreasing hemorrhage [58–61]. A meta-analysis of randomized trials and observational studies in the Asian population published in 2019 indicated that NOACs improved thera-
Table 1. On-going RCTs in patients with AF and ESRD and an unaccomplished trial on ivabradine in patients with persistent AF.

| Registration of the trial | Drug | Study design | Primary outcome | Estimated date of completing |
|--------------------------|------|--------------|-----------------|-----------------------------|
| NCT03987711              | Warfarin vs. apixaban vs. no antithrombotic therapy | Treatment effect and safety | 2021.12 |
| NCT02933697              | Low-dose apixaban vs. warfarin | Treatment safety | 2022.07 |
| NCT02886962              | Warfarin vs. nonuse | Adverse effect | 2023.01 |
| NCT03862359              | Warfarin | Treatment effect and safety | 2024.09 |
| NCT03718273              | Ivabradine vs. digoxin | Treatment effect and serious adverse outcome | 2021.08 |

Nevertheless, ESRD patients were excluded from the study, which poses a handicap in the use of NOACs.

4.2.1 Warfarin

Warfarin is a commonly used anticoagulant that mainly inhibit the vitamin K reductase and vitamin K recirculation. After being completely absorbed, warfarin takes nearly a week to reach a steady-state and is eliminated totally by metabolism [63]. Although its renal excretion is negligible, a lower dose is needed in patients with stages 4–5 CKD to achieve the correct international normalized ratio (INR).

In ESRD patients complicated with AF, high-level RCTs to provide the most striking evidence for decision-making are lacking. Previous observational real-world studies on warfarin prescription in ESRD patients do not provide consistent idea Fig. 5) [64]. Some cohort studies showed the benefits of warfarin in stroke prevention and survival (Fig. 5a,c) [65,66], while others showed no beneficial effects but greater harm (Fig. 5b) [67,68]. The American Heart Association (AHA)/American College of Cardiologists (ACC)/Heart Rhythm Society (HRS) 2019 Guideline for AF management ranked warfarin prescription as IIb indication, but in patients with ESRD and AF, less than 50% receive oral anticoagulant, and only about 34% of people receive warfarin in the dialysis population [69]. In end-stage CKD patients treated with warfarin, there were no survival benefits and decreased rate of stroke, but an elevated risk of hemorrhage events (Fig. 5) [67,70,71]. Warfarin therapy has one obvious drawback compared with direct oral anticoagulants (DOACs). The warfarin therapeutic range is critically questionable to overcome, especially for patients with poor treatment compliance. According to the AHA/ACC/HRS 2019 Guideline, patients should take coagulation function examination to determine the INR at least once a week at the initiation of warfarin treatment, and at least once a month until its efficacy is stable [57].

Moreover, warfarin may have side effects other than bleeding due to its pharmacological mechanism to inhibit vitamin K-dependent gamma-glutamyl carboxylase enzyme. Decreased vitamin K-dependent gamma-glutamyl carboxylase enzyme activation impairs matrix G1a protein (MPG). However, MPG is demonstrated to attenuate vascular calcification significantly [72]. Vascular calcification is prevalent in CKD patients, and is associated with an increased risk of cardiovascular, cerebrovascular, peripheral vascular disease [73,74]. Despite the untoward effects limit warfarin application, it is still a deemed medicine for anticoagulation when the INR is stable and the risk of bleeding is lower than stroke.

4.2.2 Non-Vitamin K Oral Anticoagulant

NOACs, also known as DOACs, and currently dabigatran, rivaroxaban, apixaban, and edoxaban are commonly used for anticoagulation. Dabigatran is a thrombin inhibitor unlike other three coagulation factor Xa inhibitors. NOACs are preferable to warfarin in NOACs-eligible AF patients [57]. However, top-level evidence for NOACs prescription is scarce in AF patients with severe renal dysfunction. Food and Drug Administration (FDA) approved only apixaban for anticoagulation in patients with ESRD, and the AHA/ACC/HRS 2019 Guideline for AF management is consistent with FDA [57]. On the contrary, the 2018 European practical guideline refused apixaban therapy in ESRD patients [75].

4.2.2.1 Apixaban. In studies comparing the efficacy and safety of apixaban with warfarin, apixaban showed its advantage in stroke and embolism prevention or less major bleeding events with fewer mortality [59,76,77]. Although warfarin was associated with a lower risk of stroke and systematic embolism in the subgroup analysis of severe or moderate renal impairment, it was statistically insignificant [59]. In a matched-cohort study, apixaban had a lower major bleeding occurrence; however, there was no significant difference [77]. In another retrospective cohort study, there were significant differences in both overall and major hemorrhagic events between apixaban and warfarin groups (18.9% vs. 42.0%; \( p = 0.01 \) and 5.4% vs. 22.0%; \( p = \))
Fig. 5. Efficiency and safety of warfarin in patients with AF and ESRD. (a) Hazard ratio (HR) for stroke treated with warfarin. (b) Hazard ratio (HR) for bleeding treated with warfarin. (c) Hazard ratio (HR) for mortality treated with warfarin. AF, atrial fibrillation; ESRD, end-stage renal disease.

0.01 respectively) (Fig. 6, Ref. [78]) [76]. A meta-analysis of observational studies in dialysis population showed that apixaban was significantly associated with lower risk of bleeding than warfarin and other DOACs (Fig. 6b) [78]. Thus, apixaban may be effectively and safely used in ESRD patients (Fig. 6a,c). We have to be aware that the therapeutic dosage of apixaban needs to be prudently adjusted according to the stroke and bleeding risks. In a small-scale study including seven dialysis patients, 5 mg twice daily was beyond a reasonable therapeutic level [79]. On the contrary, routine 5 mg twice daily was significantly associated with reduced risks of stroke and mortality (HR 0.61, 95% CI 0.37–0.98, \( p = 0.04 \)) [80]. Thus, ESRD is not a contraindication to apixaban, but a standard dose of 5 mg twice daily is not recommended for all patients.

4.2.2.2 Dabigatran. Dabigatran is not approved in patients with eGFR ≤15 mL/min/1.73 m². As the only thrombin inhibitor, dabigatran is distinguished from other NOACs because more than half of it can be eliminated by dialysis [22]. In an analysis comparing two fixed-doses (110 mg twice daily and 150 mg twice daily) of dabigatran with warfarin, higher doses gave a better response to stroke prevention but did not reduce major bleeding risks [1.11% vs. 1.69%; Risk Ratio (RR) 0.66; \( p < 0.01 \) and 3.36% vs. 3.1%; \( p = 0.31 \)]. Conversely, the 110 mg twice daily strategy was independently associated with the decreased major bleeding rate (3.36% vs. 2.71%; \( p = 0.003 \)) [58]. In another study on dialysis patients, dabigatran was at greater risk of not only lethal hemorrhage (RR 1.48; 95% CI 1.21–1.81, \( p = 0.0001 \)) but also minor bleeding (RR 1.17; 95% CI 1.00–1.38, \( p = 0.05 \)) after adjusting covariates (Fig. 6b) [81]. However, it did not show a trend to lower stroke due to the relatively short follow-up time. In severe renal impaired patients, dabigatran exposure was approximately a 6-fold increase compared with general subjects, and its elimination time was prolonged [82]. A treatment simulation suggested once-daily over twice-daily dosing in patients undergoing hemodialysis [83]. However, further studies are needed to support the use of dabigatran therapy in patients with severe kidney dysfunction.

4.2.2.3 Rivaroxaban and Edoxaban. Rivaroxaban therapy did not show significantly reduced rates of stroke and systemic embolism (RR 1.8; 95% CI 0.89–3.64) [81], and was associated with adverse effects of both severe (RR 1.38; 95% CI 1.03–1.83, \( p = 0.04 \)) and slight (RR 1.35; 95% CI 1.11–1.65, \( p = 0.001 \)) bleeding events. In a double-blind trial, the rivaroxaban (20 mg) group did reduce stroke and systemic embolism compared with the warfarin group (RR 0.88; 95% CI 0.74–1.03, \( p < 0.001 \) for inferiority) [58]. Edoxaban did not show a favorable trend in stroke and thromboembolic events prevention compared with warfarin. Thus, rivaroxaban and edoxaban may not have their place as anticoagulation options for ESRD patients.
Although we can get instructive information from observational studies with large subjects, the surrounding evidence from RCTs is limited. Several ongoing RCTs on anticoagulation drugs may provide a direction for improving embolism prophylaxis (Table 1).

5. Our New Idea on AF Management in CKD

5.1 SGLT-2 Inhibitor: Will It be a Good Choice for Patients with Mild-Moderate Renal Insufficiency to Prevent AF?

Sodium glucose cotransporter-2 (SGLT-2) is a cotransporter of Na\(^+\)-glucose located in the apical membrane of renal proximal convoluted tubule that plays a role in glucose reabsorption [84]. The latest hypoglycemic drug, SGLT-2 inhibitor acts on this transporter to decrease blood glucose. However, animal experiments indicated that SGLT-2 is widely involved in inflammation [85], tissue fibrosis and cell signaling pathways regulation [86]. More attention was given to its protective effect on the cardiovascular system than to its hypoglycemic effects. Several reviews have evidence for SGLT2i cardioprotective effects [87,88]. A meta-analysis of 22 RCTs revealed that SGLT2i was associated with decreased risk of AF (RR 0.82, 95% CI 0.70–0.96) and embolic stroke (RR 0.32, 95% CI 0.12–0.85) [89], consistent with a Chinese cohort study demonstrating that SGLT2i decreased the risk of new-onset arrhythmia [90]. Nevertheless, a previous systematic review with fewer participants took an opposite view that SGLT2i was not associated with a reduced risk of AF independently (OR 0.61, 95% CI 0.31–1.19) [91]. In patients with diabetes mellitus (DM), the application of SGLT2i ameliorated the AF occurrence events, regardless of whether the AF is absent or not previously [92]. SGLT2i can cause significant reduction in weight and blood pressure [93], which further reduces the risk of AF. Thus, it is suggested that that SGLT2i can decrease the chance of AF in patients with mild-moderate kidney failure. SGLT2i exerted the anti-inflammatory effects in rats with colitis by reducing the overexpression of proinflammatory cytokines IL-1\(\beta\) and TNF-\(\alpha\), and making the anti-inflammatory cytokine IL-10 work properly [85]. Following SGLT2 inhibition, AMP-activated protein kinase (AMPK) signal activation suppresses the nucleotide-binding domain and leucine-rich repeat-containing (NLR) family pyrin domain containing 3 (NLRP3) to mitigate inflammation [94]. It has also been proven that SGLT2i observably suppressed inflammation response in immune cells [95]. Indeed, one hallmark feature in CKD is chronic exposure to a low-grade inflammatory state. However, inflammation is a fundamental part of AF initiation and maintenance. Consequently, it is reasonable to suggest that SGLT2i can be prescribed for mild-moderate kidney dysfunction patients to prevent AF and other adverse cardiovascular events.
There are multiple possible molecular signaling pathways through which SGLT2i reduce the underlying risk of AF (Fig. 7). Sesterins are cytoplasmic stress proteins that prevent atra from oxidative damage and structural remodeling by alleviating ROS accumulation and fibrosis in cardiac fibroblasts [96]. SGLT2i upregulated Sesterin2 and then activated downstream AMPK/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, thus accounting for SGLT2i’s role in abating inflammation response, oxidative stress, and atrial fibrosis [97]. Normal physiological activities and energy metabolism of cells or organs depend on effective and functional mitochondrial respiration. Sesterin2/AMPK pathway activation enhances peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) expression, restraining ROS’s excessive production through more dynamic mitochondrial function [98,99]. Shao et al. [99] disclosed that PGC-1α nuclear respiratory factor-1 (NRF-1)/mitochondrial transcription factor A (TFAM) as the relevant molecular pathway in rat models. Another key downstream molecule of Sesterin2 is liver kinase B1 (LKB1), a crucial protein kinase for normal atrial development and electrophysiological activities. Ion channel and connexin dysfunction in LKB1 knock-down mice resulted in electrophysiological abnormalities and fibrosis of the atrium, which predispose to the AF occurrence [100]. Animal studies also revealed that SGLT2i could ameliorate electrical remodeling of the atrium [99]. These intricate and diverse molecular signaling pathways illustrated that SGLT2i inhibitions has a positive impact on the prevention of cardiovascular disease and arrhythmia. Hence, extending the SGLT2i application to treat cardiovascular events is of great significance. Thus, we suggest SGLT2i’s application to mild-moderate kidney failure population, especially with comorbid DM, HF, or multiple metabolic disorders.

5.2 LCZ696 (Sacubitril/Valsartan): Will It Be Available for AF and Stroke Prevention in the CKD Population?

Sacubitril/Valsartan (SAC/VAL) is an inhibitor of Ang II and nephrilysin receptor that blocks Ang II binding to angiotensin receptor 1 (AT-R1) and amplifies the effects of natriuretic peptides by decreasing their degradation [101]. It has been a first-class medicine for chronic heart failure, and trials by Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) investigators showed that sacubitril/valsartan significantly reduced the risk of cardiovascular mortality and admission in patients with reduced ejection fraction heart failure [102]. In severe renal insufficiency patients, the risk of death from cardiovascular disease reduced 28% in the sacubitril/valsartan group compared with conventional management [103]. Treatment with sacubitril/valsartan improved systolic cardiac function after myocardial infarction (MI), and decreased the arrhythmias tendency by decreasing CaMK II phosphorylation in rodent chronic MI and HF model [104]. Martens et al. [105] used a retrospective study including 151 eligible patients with heart failure with reduced ejection fraction (HFrEF) to demonstrate the benefit of sacubitril/valsartan therapy for ventricular arrhythmia and reversal of left ventricular structural remodeling. Data from pre-clinical trials suggested that sacubitril/valsartan ameliorates cardiac fibroblast transition by accommodating protein kinase G (PKG) signaling [106]. Li et al. [107] also found NF-kB/NLRP3 signaling pathway involved in positive effects of LCZ696 to prevent cardiac fibrosis in mice. Except for averting ventricular reconstruction, atrial electrophysiological dysfunction and structural remodeling in rabbits afflicted with AF were converted significantly by sacubitril/valsartan through the calcineurin/NFAT pathway [108], which further hindered initiation and progression of AF.

Li et al. [109] demonstrated that SAC/VAL altered atrial fibrillation propensity by suppressing Ang II-induced AF in rat models. Interestingly, they also noticed p-Smad 2/3, phosphorylation of c-jun-NH2-terminal kinase (p-JNK) and p-p38MAPK downregulated expression, indicating that it might be a potential therapeutic target pathway. Sacubitril/valsartan could strongly improve left atrial (LA) and left atrial appendage (LAA) function even in AF patients [110]. Fully effective LA and LAA function are essential for escaping from blood stagnation and thrombogenesis and reducing cardioembolic stroke risk [111]. A meta-analysis of SAC/VAL in renal failure and AF patients showed that it reserved kidney function without adverse drug reaction [112]. In a mouse model of CKD, LCZ696 attenuated oxidative stress, fibrosis and inflammation in the kidney as well as the cardiovascular system [113,114]. The above evidence (Fig. 8) adds to our understanding of sacubitril/valsartan therapy’s role in preventing AF occurrence and stroke in patients with AF and CKD. Atrial disease is an important part in the development and progression of HF, meanwhile, patients with HF prone to AF [115], which suggests that it is necessary to treat HF in patients with CKD.

6. LAAO in Patients with AF and CKD

The left atrial appendage (LAA) is the main thrombogenesis region in AF for its poor function, and if that the thrombus falls off, a systematic embolic outcome follows. The left atrial appendage occlusion (LAAO) is an optimal mechanical strategy for preventing AF-related stroke [116]. In real-world clinical practice, patients who received LAAO therapy had a lower risk of stroke and hemorrhage [117]. Considering the uncertainty in the pros and cons of anticoagulants use in patients with advanced renal failure, LAAO may be a suitable stroke prevention strategy [118]. Kefer et al. [119] highlighted that LAAO greatly reduced the risk of stroke, transient ischemic attacks (TIA), and bleeding events. In a meta-analysis comparing the benefits and adverse outcomes between LAAO and anticoagulants, it has been indicated that LAAO acquired more ef-
Fig. 7. SGLT2i exerts an influence on protecting the cardiovascular system. SGLT2i, sodium-glucose cotransporter inhibitor; Glu, glucose.

Fig. 8. Sacubitril/valsartan was demonstrated to be a beneficial option for AF patients. AF, atrial fibrillation; CKD, chronic kidney disease; LA, left atrium; LAA, left atrial appendage.

Effective embolism prevention with a lower risk of bleeding than oral anticoagulants [120]. Therefore, LAAO can be proposed for CKD patients with absolute contraindication to oral anticoagulants.

7. Early Identification of AF is Required in Patients with CKD

Early identification of AF is beneficial for patients with renal insufficiency, and early diagnosis of asymptomatic AF helps prevent stroke effectively. However, screening for AF is not routinely performed in patients with CKD. LA imaging technology, such as 2-dimensional echocardiogram, 3-dimensional echocardiogram, cardiac magnetic resonance, and cardiac computed tomography, have been used to accurately assess LA size and function [121]. Besides, cardiac troponin and natriuretic peptide are serological markers suggestive of cardiovascular dysfunction. Molecular imaging may also enable accurate and early
better management. At-risk patients with CKD are at high risk for AF, therefore, we need a comprehensive strategy, which includes risk factor assessment, sensitive serum biomarkers, precise imaging, and promising molecular imaging for better management.

8. Summary

AF and CKD usually coexist and share several common traditional risk factors. CKD patients possess underlying pathophysiological mechanisms in the initiation and development of AF, and making treatment decisions for stroke prevention in this population remains a challenge. In this review, a series of innovative measures for AF management in CKD patients were brought forward, but these strategies were just hypotheses with sound reasoning. Thus, individualized prevention and therapy strategies for AF are still required in patients with CKD.

Author Contributions

FH and YY provided conceptualization. YW prepared the original draft. YY and YW contributed to editorial changes in the manuscript. FH contributed to supervision. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

Not applicable.

Funding

This work was supported by National Natural Science Foundation of China Grants NSFC [81974089], and the Frontier Application Basic Project of the Wuhan Science and Technology Bureau [2020020601012235].

Conflict of Interest

The authors declare no conflict of interest.

References

[1] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020; 395: 709–733.

[2] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association. Circulation. 2019; 139: e56–e528.

[3] Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation Research. 2017; 120: 1501–1517.

[4] Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation. 1998; 98: 946–952.

[5] Khoury Y, Stephens T, Ayuba G, AlAmeri H, Juratli N, McCullough PA. Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. Journal of Atrial Fibrillation. 2015; 7: 1069.

[6] Ding WY, Gupta D, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovascular Research. 2021; 117: 1046–1059.

[7] Kotaleczyk A, Ding WY, Wong CF, Rao A, Gupta D, Lip GYH. Atrial Fibrillation in Patients with Chronic Kidney Disease. Cardiology Clinics. 2021; 39: 435–446.

[8] Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. American Heart Journal. 2009; 158: 629–636.

[9] Hart RG, Eikelboom JW, Brimble KS, McMurry MS, Ingram AJ. Stroke Prevention in Atrial Fibrillation Patients with Chronic Kidney Disease. Canadian Journal of Cardiology. 2013; 29: S71–S78.

[10] Hindricks G, Poppara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021; 42: 373–498.

[11] Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney International. 2012; 81: 469–476.

[12] Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic Kidney Disease is Associated with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 2946–2953.

[13] Bansal N, Xie D, Tao K, Chen J, Deo R, Horwitz E, et al. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clinical Journal of the American Society of Nephrology. 2016; 11: 1189–1196.

[14] Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrology Dialysis Transplantation. 2012; 27: 3816–3825.

[15] Clark DM, Plumb VI, Epstein AE, Kay GN. Hemodynamic Effects of an Irregular Sequence of Ventricular Cycle Lengths during Atrial Fibrillation. Journal of the American College of Cardiology. 1997; 30: 1039–1045.

[16] Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm. 2014; 11: 1752–1759.

[17] Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial Fibrillation and Morbidity and Mortality in a Cohort of Long-term Hemodialysis Patients. American Journal of Kidney Diseases. 2008; 51: 255–262.

[18] Shih CJ, Ou SM, Chao PW, Kuo SC, Lee YJ, Yang CY, et al. Risks of Death and Stroke in Patients Undergoing Hemodialysis with New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort. Circulation. 2016; 133: 265–272.

[19] Bansal N, Xie D, Sha D, Appel LJ, Deo R, Feldman HI, et al. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology. 2018; 29: 2859–2869.

[20] Bansal N, Fan D, Hsu C, Ondez JD, Marcus GM, Go AS. Incident Atrial Fibrillation and Risk of End-Stage Renal Disease...
Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019; 74: 2204–2215.

Chen KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S, et al. Nonvitamin K Anticoagulant Agents in Patients with Advanced Chronic Kidney Disease or on Dialysis with AF. Journal of the American College of Cardiology. 2016; 67: 2888–2899.

Wakili R, Voigt N, Käihä S, Dobrev D, Nettel S. Recent advances in the molecular pathophysiology of atrial fibrillation. Journal of Clinical Investigation. 2011; 121: 2955–2968.

Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous Initiation of Atrial Fibrillation by Escape Beats Originating in the Pulmonary Veins. New England Journal of Medicine. 1998; 339: 659–666.

Nettle S. Paroxysmal Atrial Fibrillation and Pulmonary Veins: Relationships between Clinical Forms and Automatic Versus re-entrant Mechanisms. Canadian Journal of Cardiology. 2013; 29: 1147–1149.

Heijman J, Voigt N, Nettel S, Dobrev D. Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression. Circulation Research. 2014; 114: 1483–1499.

Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, et al. Cellular and Molecular Mechanisms of Atrial Arrhythmogenesis in Patients with Paroxysmal Atrial Fibrillation. Circulation. 2014; 129: 145–156.

Molina CE, Abu-Taha IH, Wang Q, Rosello-Diez E, Kammers M, Nettel S, et al. Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients with and Without Atrial Fibrillation. Frontiers in Physiology. 2018; 9: 1383.

Sood S, Chelu MG, van Oort RJ, Skapura D, Santonastasi M, Dobrev D, et al. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm. 2008; 5: 1047–1054.

Chen P, Chen LS, Fishbein MC, Lin S, Nettel S. Role of the Autonomic Nervous System in Atrial Fibrillation. Circulation Research. 2014; 114: 1500–1515.

Landray MJ, Wheeler DC, Lip GYH, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. American Journal of Kidney Diseases. 2004; 43: 244–253.

Yeyati NL, Adrogue HJ. Inappropriately High Plasma Renin Activity Accompanies Chronic Loss of Renal Function. American Journal of Nephrology. 1996; 16: 471–477.

Jüppner H. Phosphate and FGF-23. Kidney International. 2011; 79: S24–S27.

Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Muka- mal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). Journal of the American College of Cardiology. 2012; 60: 200–207.

Lutsey PL, Alonso AP, Patel MR, Abrahamson S, Michos ED, Agarwal SK, et al. Fibroblast Growth Factor-23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association. 2014; 3: e000936.

Seiler S, Cremers B, Rebling NM, Hornof F, Jekem J, Kersting S, et al. The phosphatonin fibroblast growth factor 23 links calcium–phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. European Heart Journal. 2011; 32: 2688–2696.

Grabner A, Amaral A, Schramm K, Singh S, Sloan A, Yanucili C, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metabolism. 2015; 22: 1020–1032.

Faul C, Amaral AF, Oskouei B, Hu M, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation. 2011; 121: 4393–4408.

Mathew JS, Sachu MC, Katz R, Paton KK, Heckbert SR, Hoofnagle AN, et al. Fibroblast Growth Factor-23 and Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation. 2014; 130: 298–307.

Verbeuken D, Moe OW. Strategies to lower fibroblast growth factor-23 bioactivity. Nephrology Dialysis Transplantation. 2021; gfa012. (in press)

Singh S, Grabner A, Yanucili C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney International. 2016; 90: 985–996.

Dong Q, Li S, Wang W, Han L, Xia Z, Wu Y, et al. FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways. Journal of Cellular Physiology. 2019; 234: 19502–19510.

Aoki K, Teshima Y, Kondo H, Saito S, Fukuai A, Fukunaga N, et al. Role of Indoxyl Sulfate as a Predisposing Factor for Atrial Fibrillation in Renal Dysfunction. Journal of the American Heart Association. 2015; 4: e002023.

Chen WT, Chen YC, Hsieh MH, Huang SY, Kao YH, Chen YA, et al. The Uremic Toxin Indoxyl Sulfate Increases Pulmonary Vein and Atrial Arrhythmogenesis. Journal of Cardiovascular Electrophysiology. 2015; 26: 203–210.

Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Kram H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? European Heart Journal. 2010; 31: 1711–1779.

Ellis RJ, Small DM, Vesey DA, Johnson DW, Francis R, Vetten L, et al. Indoxyl sulphate and kidney disease: Causes, consequences and interventions. Nephrology. 2016; 21: 170–177.

Boriani G, Savelieva I, Dan G, Deharo JC, Ferro C, Israel CW, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015; 17: 1169–1196.

Aronov WS. Acute and Chronic Management of Atrial Fibrillation in Patients with Late-Stage CKD. American Journal of Kidney Diseases. 2009; 53: 701–710.

St Peter WL, Sozio SM, Shafii T, Ephraim PL, Luly J, McDermott A, et al. Patterns in blood pressure medication use in us incident dialysis patients over the first 6 months. BMC Nephrology. 2013; 14: 249.

Assimon MM, Brokhart MA, Fine JP, Heiss G, Layton JB, Flytche JE. A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality among Individuals Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases. 2018; 72: 337–348.

Lin TT, Chiang JY, Liao MT, Tsai CT, Hwang JJ, Chiang FT, et al. Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. Scientific Reports. 2015; 5: 17731.

Turakhia MP, Blankstijn PJ, Carrero JJ, Clase CM, Deo R, Her- zog CA, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal. 2018; 39: 2314–2325.

Tanboğa İH, Topçu S, Aksakal E, Gulcu O, Aksakal E, Aksu et al.
U, et al. The Risk of Atrial Fibrillation with Ivrabradine Treatment: a Meta-analysis with Trial Sequential Analysis of more than 40000 Patients. Clinical Cardiology. 2016; 39: 615–620.

[54] Wang Z, Wang W, Li H, Zhang A, Han Y, Wang J, et al. Ivrabradine and Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology. 2021. (in press).

[55] Fontenla A, López-Gil M, Tamargo-Menéndez J, Matía-Françès R, Salgado-Aranda R, Rey-Blas JR, et al. Ivrabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project. Revista Española de Cardiología. 2020; 73: 368–375.

[56] Navaravong L, Barakat M, Burgon N, Mahnkopf C, Koopmann M, Ranjan R, et al. Improvement in Estimated Glomerular Filtration Rate in Patients with Chronic Kidney Disease Undergoing Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2015; 26: 21–27.

[57] January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140: e125–e151.

[58] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361: 1139–1151.

[59] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011; 365: 981–992.

[60] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 2011; 365: 883–891.

[61] Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2013; 369: 2093–2104.

[62] Xue Z, Zhang H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians with Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies. Stroke. 2019; 50: 2819–2828.

[63] Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clinical Pharmacokinetics. 1986; 11: 483–504.

[64] Tan J, Liu S, Segal JB, Alexander GC, McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrology. 2016; 17: 157.

[65] Olesen JB, Lip GYH, Kamper A, Hommel K, Köber L, Lane DA, et al. Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. New England Journal of Medicine. 2012; 367: 625–635.

[66] Brancaccio D, Neri L, Bellocchio F, Barbieri C, Amato C, Mari F, et al. Patients’ Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study. American Journal of Nephrology. 2016; 44: 258–267.

[67] Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis. Circulation. 2014; 129: 1196–1203.

[68] Chan KE, Lazarus JM, Thadaani R, Hakim RM. Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. Journal of the American Society of Nephrology. 2009; 20: 2223–2233.

[69] Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. American Journal of Kidney Diseases. 2017; 69: S261–S300.

[70] Winkelmyer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation. Clinical Journal of the American Society of Nephrology. 2011; 6: 2662–2668.

[71] Nochowong S, Engorn C, Awiphan R, Dandecha P, Noppakun K, Phrommintikul A. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016; 3: e000441.

[72] Siltari A, Vapatalo H. Vascular Calcification, Vitamin K and Warfarin Therapy - Possible or Plausible Connection? Basic and Clinical Pharmacology and Toxicology. 2018; 122: 19–24.

[73] Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death among Patients with Chronic Kidney Disease. JAMA Cardiology. 2017; 2: 635–643.

[74] Viegas C, Araújo N, Marreiros C, Simes D. The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging. 2019; 11: 4274–4299.

[75] Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018; 39: 1330–1393.

[76] Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Research and Practice in Thrombosis and Haemostasis. 2018; 2: 291–298.

[77] Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017; 37: 412–419.

[78] Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, et al. Oral Anticoagulation for Patients with Atrial Fibrillation on Long-Term Hemodialysis. Journal of the American College of Cardiology. 2020; 75: 273–285.

[79] Mavrakanas TA, Sanner CF, Nessim SJ, Frisch G, Lipman ML. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. Journal of the American Society of Nephrology. 2017; 28: 2241–2248.

[80] Sointis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes Associated with Apixaban Use in Patients with End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018; 138: 1519–1529.

[81] Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis. Circulation. 2015; 131: 972–979.

[82] Stangier J, Rathgen K, Stähle H, Mazur D. Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Eteoxetane: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics. 2010; 49: 259–268.

[83] Liesenfeld KH, Clemens A, Kreuzer J, Bruckmann M, Schulze F. Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thrombosis and Haemostasis. 2016; 115: 562–569.

[84] Wright EM, Loo DDF, Hirayama BA. Biology of Human Sodium Glucose Transporters. Physiological Reviews. 2011; 91: 733–794.

[85] Morsy MA, Khalaf HM, Rifaii RA, Bayoumi AMA, Khalifa EMMA, Ibrahim YF. Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glu-
cose metabolism and inhibiting NOX2. Biomedicine and Pharmacotherapy. 2021; 141: 111902.

[86] Ala M. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology. 2021; 162: bqab157.

[87] Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. JACC. State-of-the-Art Review. Journal of the American College of Cardiology. 2018; 72: 1845–1855.

[88] Fei Y, Tsoi M, Cheung BMY. Cardiovascular outcomes in trials of new anti-diabetic drug classes: a network meta-analysis. Cardiovascular Diabetology. 2019; 18: 112.

[89] Li H, Lip GYH, Feng Q, Fei Y, Tse Y, Wu M, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovascular Diabetes. 2021; 20: 100.

[90] Chen H, Huang J, Siao W, Jong G. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovascular Diabetes. 2020; 19: 73.

[91] Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 2018; 25: 495–502.

[92] Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Li SN, Zhang JR, Zhou L, Xi H, Li CY, Zhao L. Sacubitril/Valsartan in heart failure: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease. 2016; 7: 278–290.

[93] McMurray JJV, Packer M, Desai AS, Gong J, Leetkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014; 371: 993–1004.

[94] Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. Journal of Cardiology. 2019; 74: 372–380.

[95] Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clinical Research in Cardiology. 2019; 108: 1074–1082.

[96] Burke RM, Lighthhouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibrobasts. Circulation. 2019; 12: e005565.

[97] Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L, et al. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice. Cardiovascular Drugs and Therapy. 2020; 34: 629–640.

[98] Li LY, Lou Q, Liu GZ, Yun FX, Li TK, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. European Journal of Pharmacology. 2020; 881: 173120.

[99] Li SN, Zhang JR, Zhou L, Xi H, Li CY, Zhao L. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways. Journal of Cardiovascular Translational Research. 2021. (in press)

[100] Suo Y, Yuan M, Li H, Zhang Y, Li Y, Fu H, et al. Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients with Atrial Fibrillation and in Pressure Overload-Induced Mice. Frontiers in Physiology. 2019; 10: 1285.

[101] Takada T, Yasaka M, Nagatsuka K, Minematsu K, Yamaguchi Sun X, Han F, Lu Q, Li X, Ren D, Zhang J, et al. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice. Diabetes. 2020; 69: 1292–1305.

[102] van der Pluijm I, Burger J, van Heijningen PM, IJpma A, van McMurray JJV, Packer M, Desai AS, Gong J, Leetkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014; 371: 993–1004.

[103] Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. Journal of Cardiology. 2019; 74: 372–380.

[104] Chang PC, Wo HT, Lee HL, Lin SF, Chu Y, Wen MS, Wen Z, et al. Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model. Journal of Cardiac Failure. 2020; 26: 527–537.

[105] Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clinical Research in Cardiology. 2019; 108: 1074–1082.

[106] Burke RM, Lighthhouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibrobasts. Circulation. 2019; 12: e005565.

[107] Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L, et al. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice. Cardiovascular Drugs and Therapy. 2020; 34: 629–640.

[108] Li LY, Lou Q, Liu GZ, Yun FX, Li TK, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. European Journal of Pharmacology. 2020; 881: 173120.

[109] Li SN, Zhang JR, Zhou L, Xi H, Li CY, Zhao L. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways. Journal of Cardiovascular Translational Research. 2021. (in press)

[110] Suo Y, Yuan M, Li H, Zhang Y, Li Y, Fu H, et al. Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients with Atrial Fibrillation and in Pressure Overload-Induced Mice. Frontiers in Physiology. 2019; 10: 1285.

[111] Takada T, Yasaka M, Nagatsuka K, Minematsu K, Yamaguchi T. Blood Flow in the Left Atrial Appendage and Embolic Stroke in Nonvalvular Atrial Fibrillation. European Neurology. 2001; 46: 148–152.

[112] Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. European Journal of Pharmacology. 2020; 884: 173444.

[113] Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaei M, et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. American Journal of Translational Research. 2017; 9: 5473–5484.

[114] Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaei M, Vaziri ND, et al. LCZ696 (Sacubitril/Valtsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. Journal of Cardiac Failure. 2018; 24: 266–275.

[115] Coats AJS, Heymans S, Farmakis D, Anker SD, Bakers J, Bauersachs J, et al. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association
of the European Society of Cardiology. European Heart Journal. 2021. (in press)

[116] Price MJ, Valderrábano M. Left Atrial Appendage Closure to Prevent Stroke in Patients with Atrial Fibrillation. Circulation. 2014; 130: 202–212.

[117] Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage. Circulation: Arrhythmia and Electrophysiology. 2019; 12: e006841.

[118] Black-Maier E, Piccini JP, Granger CB. Left atrial appendage closure: a therapy uniquely suited for specific populations of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2019; 30: 2968–2976.

[119] Kefer J, Tzikas A, Freixa X, Shakir S, Gafoor S, Nielsen-Kudsk JE, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. International Journal of Cardiology. 2016; 207: 335–340.

[120] Zhang HF, Zhang QX, Zhang YY, Yang D, Xu Z, Jiao QB, et al. Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Reviews in Cardiovascular Medicine. 2020; 21: 443.

[121] To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA imaging: assessment of size, function, and structure. JACC: Cardiovascular Imaging. 2011; 4: 788–798.

[122] Ezeani M, Hagemeyer CE, Lal S, Niego B. Molecular imaging of atrial myopathy: Towards early AF detection and non-invasive disease management. Trends in Cardiovascular Medicine. 2022; 32: 20–31.